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Where are we coming from? 
For a new technology, high field cardiac MR (CMR, 3.0 Tesla ≤ B0 ≤7.0 Tesla) has come 
a long way. Not only has the number of reports referencing clinical applications risen 
1, 2 but prices for 3.0 T systems have dropped almost 50% since the beginning of the 
millenniumand operational and service costs are virtually identical to those of 1.5 T 
machines. New 3.0 T installations make up about 25% of the total market share and 
are increasing at an annual growth rate of 10%. High field comprised approximately 
25 % of the abstracts in CMR submitted to the most recent annual meetings of the 
Society for Cardiac Magnetic Resonance (SCMR) and the International Society for 
Magnetic Resonance in Medicine (ISMRM). Large-population studies targeting the 
heart are now being conducted at 3.0 T, including imaging within the framework of 
the German National Cohort 3. The advances in CMR at high magnetic field strengths 
foreshadow some of the potential benefits to be expected as the technology moves 
to ultrahigh fields (UHF, B0 ≥7.0 Tesla). 
 
Where do we stand? 
The future of high field CMR has obviously not ended at 3.0 T and is moving higher. 
Technical barriers are being addressed almost as fast as they appear. Clinical CMR at 
ultrahigh field strengths is rapidly underway4-6. About 15% of sites already equipped 
with a 7.0 T MR system have begun exploring UHF-CMR, with 50 peer-reviewed 
publications on human imaging.  Early UHF-CMR applications include imaging and 
spectroscopy of the heart and large vessels 7-22. This can be achieved due to the 
inherent relationship between the signal-to-noise ratio (SNR) and magnetic field 
strength. In parallel, the field is making remarkable progress with respect to novel 
radiofrequency (RF) technologies 20, 23, 24 and MR methods that should make clinical 
UHF-CMR feasible as 7.0 T MR machines become more widely available.  
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Ultimately, we may see a solution to practical and technical issues that need to be 
resolved before UHF-CMR could move into clinical settings 25; but these challenges 
have always faced new technologies.  As is customary, we can expect more 
pioneering research institutions, university hospitals and large clinics to become early 
adopters of CMR at 7.0 Tesla and start harvesting knowledge and know-how that will 
benefit us all.  Streamlining hardware and software platforms and making them more 
robust should permit feasibility studies into CMR on which future applications will be 
built. These research instruments and activities are dedicated to exploring 
opportunities for discovery; at some point the knowledge gained could surely justify 
the cost. This has been the case in the past, and the investment and operating costs 
of a 7.0 T MR facility can expect to draw on the same types of private-public 
partnerships, core facility reimbursement models, institutional funding and extramural 
grants that are traditional mechanisms supporting high-end facilities in many institutes 
today. 
 
Where can UHF-CMR expect to harvest new discoveries? 
It has been extremely challenging to connect the molecular and cellular defects that 
characterize many cardiac diseases to the level of major organ systems at which 
they play themselves out. Here MRI has a capacity that is nearly unique among 
instruments: to simultaneously measure many levels of physiological structure, linking 
the scales of biologists to those of clinicians, in vivo. UHF-CMR stands to bridge a 
crucial gap in spatiotemporal resolution at a mesoscopic level above that of the cell, 
a terrain that is crucial to myocardial and pathological processes but has been 
difficult to explore. 
 
 
Cardiovascular morphology and cardiac chamber quantification 
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UHF-MR may help extend the boundaries of CMR by facilitating high spatial resolution 
imaging  of cardiovascular morphology, as demonstrated in Figure 1, derived from 
black blood imaging of the human heart at 7.0 T. A spatial resolution of 0.9 x 0.9 x 4.0 
mm3 was applied, representing an enhancement by an  order of magnitude over the 
standardized CMR protocols practiced in clinics today 26.   
Plaque imaging, arterial wall imaging and carotid wall imaging are applications that 
perhaps demand highest spatial resolution. Figure 1 depicts preliminary results 
obtained from 2D dark blood fast spin-echo imaging of the carotid artery wall at 7.0 T 
using an in-plane spatial resolution of (0.6 x 0.6) mm2. A spatial resolution of 
(0.4 × 0.4 × 1.5) mm3 was demonstrated for the normal carotid vessel wall using T1 
weighted dark blood fast spin-echo imaging at 7.0 T 27. A quantitative comparison 
revealed a twofold average gain in SNR (Table 1) 27. T1 relaxation time of the normal 
carotid vessel wall was 1628 ms at 7.0 T (3.0 T: T1=1227 ms), while a T2 relaxation time of 
46 ms was observed at 7.0 T (3.0 T: T2=55 ms) 27. 
Early studies confirmed that UHF-CMR can be used for cardiac chamber 
quantification of the left 8, 12, 13 and the right ventricle 16 using high density arrays of RF 
antennae (Figure 2) 20, 23, 24, 28-30. These studies reported a SNR increase 2.1-time (Table 
1) for 7.0 T versus 1.5 T 12. This favorable effect produces blood myocardium contrast 
which is competitive with that obtained for 2D CINE SSFP imaging at 1.5 T, high-quality 
images with a uniform signal intensity and high blood/myocardium contrast over the 
entire heart as illustrated in Figure 3 and Video 1 in the online supplemental material. 
The latter depicts short axis views covering the heart from the apex to the base and 
demonstrates rather uniform signal intensity across the heart facilitated by a modular 
32 channel transceiver loop antenna RF array at 7.0 T20. Figure 3 depicts four 
chamber and short-axis views of the heart obtained with a standardized CMR 
protocol 26 and compares them with a protocol that enhances spatial resolution. The 
latter reduces the voxel size from 19.4 mm3 to 3.0 mm3, a six-fold improvement in 
spatial resolution over a standardized clinical CMR protocol 26. This fidelity 
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approaches the relative anatomical spatial resolution - in terms of number of voxels 
with respect to  anatomy – demonstrated for animal models 31. This achievement is 
translatable into opportunities for discovery, including the ability to detect subtle 
myocardial crypts (Figure 4) that often appear in conjunction with hypertrophic 
cardiomyopathy 32. High spatial fidelity gradient echo 2D CINE imaging at 7.0T 
permits the identification of such subtle morphological details in myocardial regions 
of extended hypertrophy and fibrosis 5. These structures have not been detectable in 
this particular myocardial region at current clinical field strengths in the same patient 
and may yield new insights into developmental aspects of myocardial remodeling 5. 
These preliminary results warrant further research in human subjects and animal 
models to link and validate the UHF-CMR mesoscopic imaging observations with 
pathologic findings, HCM phenotypes and molecular mechanisms of the disease.  
 
Real-time MRI of the heart 
UHF-CMR provides an unprecedented potential for real-time imaging and addressing 
some of the shortcomings and physiological constraints of traditional assessments of 
LV and RV structure and function. The accelerated imaging capabilities of free 
breathing real time imaging of the heart at 7.0 T are demonstrated in Figure 5. The 
spatial resolution of (1.2 x 1.2 x 6.0) mm3 and the frame rate of 30 frames per second 
surpass the requirements established by current clinical protocols for standardized 
assessments of LV structure and function 26. The findings from such studies may be 
extrapolated to clinical CMR studies at lower spatial and temporal resolutions, which 
may enhance their clinical utility.  
 
Myocardial tissue characterization and phenotyping 
UHF-CMR opens new avenues into myocardial tissue characterization and 
phenotyping by mapping the effective transverse relaxation time T2*. The linear 
relationship between magnetic field strength and microscopic susceptibility effects 
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makes 7.0 T an appealing avenue for T2* mapping 17. This will permit observing 
enhanced susceptibility effects by lowering the detection level for abnormal tissue as 
compared to low field MR, and extending the dynamic range of sensitivity for 
monitoring T2* changes.  
By reducing the in-phase inter-echo time from 4.8 ms at 1.5 T to 1.02 ms at 7.0 T, UHF-
CMR can acquire multiple gradient echoes 14. Unlike single cardiac phase T2* 
mapping at lower fields, UHF-CMR permits 2D CINE T2* mapping across the entire 
cardiac cycle. Phase-resolved, high resolution T2* maps have been made of the 
human heart in vivo at 7.0 T 14, 22. Temporal changes in T2* across the cardiac cycle 
are not assessable  at 1.5 or 3.0 T due to scan time constraints. CINE T2* mapping at 
7.0 Tesla accomplishes this, reporting cyclic changes in septal T2* with a mean 
increase of end-systolic T2* of about 10% compared to end-diastole 22. The periodic 
changes in interventricular septal myocardial T2* correlate well with changes in the 
thickness of the septal wall and the left-ventricular radius throughout the cardiac 
cycle (Figure 6). Cyclic T2* variations were attributed to changes in myocardial blood 
volume fraction rather than oxygenation, an example of the unique information that  
temporally resolved MR relaxation mapping can reveal about cardiac 
(patho)physiology in vivo 22.  
The first cardiac T2* maps made at 7.0 T of hypertrophic cardiomyopathy demonstrate 
that septal T2* is increased in patients compared to healthy controls 4 as illustrated in 
Figure 6. A mean septal T2* of 17. 5 ms for HCM patients and of 13.7 ms for healthy 
subjects matched by body mass index and age were reported4. These findings 
suggest that T2* mapping at UHF could provide an important imaging based 
biomarker in support of diagnoses and risk stratification in cardiomyopathies. 
 
Heteronuclear MRI for metabolic and nanomolecular probing 
The greater spectral resolution and sensitivity gain of UHF-MR helps clinicians and 
researchers to move beyond conventional 1H imaging to study other MR nuclei that 
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are more relevant to cardiac metabolism. The higher magnetic fields permit imaging 
phosphorous (31P), sodium (23Na), fluorine (19F), carbon (13C), oxygen (17O), potassium 
(39K), chlorine (35Cl) and other nuclei. Each new substance adds greater dimension to 
our view of cardiac metabolism, bioenergetics and tissue function in ways that should 
help us integrate our knowledge of events at the molecular scale and their effects on 
a higher level.  
Sodium MRI (23Na MRI), for example, can provide clearer insights into ion homeostasis. 
Currently, clinical applications are limited by the rapidly decaying 23Na signal and the 
low sensitivity of 23Na MRI versus 1H MR. The gain of sensitivity at 7.0 T, permitted three-
dimensional  23Na imaging of the entire heart with a spatial resolution of (6 x 6 x 6) 
mm3 in clinically acceptable acquisition times of <10 minutes 33. Information from high 
fields will very likely be applicable in the reverse direction – new associations revealed 
by 23Na will shed light on conventionally acquired 1H imaging data and help 
clinicians interpret observations at lower field strengths. The signal intensity gain at 7.0 
T has recently enabled CINE 23Na imaging of the beating heart at a temporal 
resolution of 100 ms 34 as illustrated in Figure 7. Feasibility studies of 23Na MRI at 7.0 T 
should reveal the diagnostic value of this tool in distinguishing viable from non-viable 
tissue in ischemic heart disease patients. It may also offer deeper insights into 
hypertrophic cardiomyopathy, due to reports that this condition is accompanied by 
a 33% decrease in Na+,K+-ATPase activity and a 40% increase in intracellular Na+ 
concentrations. 
Potassium ions (K+) play a vital role in myocardial function. While extracellular K+ 
concentrations can easily be estimated from laboratory analysis of blood samples, a 
method for measuring the intracellular K+ content in vivo is greatly  needed and 
would permit novel insights into pathophysiological processes of cardiac diseases, 
including arrhythmias. Potassium MRI is quite challenging since the sensitivity is about 
six orders of magnitude less than that of 1H MRI. The sensitivity gain of 7.0 Tesla will 
enable for the first time quantitative in vivo assessment of the cellular potassium 
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content in myocardium. This approach opens an entirely new research field of MRI-
driven phenotyping as a link to personalized medicine. 
Phosphorus MR at higher fields will permit new observations of energy metabolism in 
vivo. The sensitivity gain at ultrahigh magnetic fields has been demonstrated in 
comparisons between cardiac 31P-MRS at 7.0 T and 3.0 T 19, which highlighted the 
marked superiority of cardiac 31P spectra at 7.0 T as shown in Figure 8. SNR 
improvements of 2.6 - 2.8  (Table 1) for phosphocreatine (PCr) together with a 
reduced standard deviation for the PCr/ATP ratio were observed, permitting 
enhanced quantification of the phosphocreatine/adenosine triphosphate (ATP) 
concentration ratio 19. 7.0 Tesla should quickly become the field strength of choice for 
probing myocardial energetics with cardiac 31P MR spectroscopy 19. This conclusion is 
supported by the first study of this type, performed in a cohort of 25 patients with 
dilated cardiomyopathy (DCM) 6. The PCr/ATP ratio was found to be significantly 
lower in DCM patients than in healthy control subjects (Figure 8). These results are a 
precursor to broader clinical studies aiming to assess the effect of “energy sparing” 
drugs in patients with DCM 6.  
Fluorine magnetic resonance (19F MR) is a valuable tool for in vivo tracking and 
quantification of fluorine-containing exogenous agents, such as emulsified 
perfluorcarbon tracer or 19F labeled cells. Natural fluorine is virtually absent in body 
tissue, so 19MRI yields background-free images with complete signal selectivity and 
specificity.  19F detection is currently beyond the sensitivity of most clinical apparatus 
at lower field strengths, due to signal-to-noise constraints related to reproducibility; 
this is reflected by the low number of reports in the literature to date. UHF-MR can 
perform 19F MRI in vivo through the design of dedicated RF antennae. Applications 
might include in vivo monitoring of the inflammatory response to acute myocardial 
infarction and early ventricular remodeling, as well as studies of the bioavailability 
and pharmacokinetics of 19F-containing drugs and 19F-labelled cells. 
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Vascular UHF-MRI 
Another common cardiovascular application of MR that stands to benefit from higher 
field strengths is the angiography (MRA) of the large vessels. The SNR gain and the 
reduction in the geometry factor (g-factor) can be used to counter noise 
amplification caused by the acceleration techniques necessary for real time MRA, in 
order to achieve high spatiotemporal resolution MRA and for scan time shortening.  
UHF-MRA permits larger FOV’s along the head-feet direction over current short bore 
low field MR scanners due to the longer magnet and the better B0-uniformity along 
the z-direction. Local transmit/receive RF coil arrays tailored for UHF-CMR support 
anatomic coverage required for MR of large vessels as demonstrated in Figure 9 (left, 
center) for a FOVhead-feet=35 cm for free breathing real time imaging (spatial 
resolution=1.2 x 1.2 x 6.0 mm3) and segmented CINE imaging (spatial resolution=1.1 x 
1.1 x 2.5 mm3) of the human aorta. Another potential application includes large 
volume coverage, time-resolved phase velocity MRA (4D flow), used to study flow 
patterns and wall shear stress in large vessels. Aortic 4D flow imaging has recently 
been demonstrated as feasible at 7.0 T  using 1.2 mm isotropic spatial resolution 
(Figure 9, right) 35. SNR quantification of 4D aortic flow imaging at 7.0 T revealed 2.2 
times the SNR of 3.0 T and 3.8 times the SNR of 1.5 T (Table 1), which is in accordance 
with theoretical considerations 21. The baseline SNR advantage of UHF-MR also 
translates into better spatiotemporal resolution in contrast-enhanced MR 
angiography. Quantification of contrast enhancement of 4D aortic flow imaging 
showed that SNR gains achieved by contrast-enhanced versus non-enhanced MRA 
of the descending aorta were 1.8-fold at 1.5T, 1.7-fold at 3T, and 1.4-fold at 7T21.  
The capabilities of non-contrast UHF-MRA were demonstrated for high spatial 
resolution (0.45 x 0.45 x 1.2 mm3) coronary artery imaging (CAI) 18, which revealed 
enhancements in coronary vessel edge sharpness at 7.0 T over state-of-the-art CAI at 
3.0 T. SNR of the RCA blood pool was found to be increased (163 %, Table 1) at 7.0 T 
versus 3.0 T 10. These improvements should also benefit coronary vessel wall imaging 
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including preliminary results obtained with a spatial resolution of 0.86 x 0.86 x 1.2 mm3 
10. 
At ultrahigh magnetic fields the T1 prolongation of tissue and blood (7.0 T: T1,blood=2.09 
s, 3.0 T: T1,blood=1.65 s, 1.5 T: T1,blood=1.48 s) improves the suppression of background 
tissue signal, enhances the vessel-to-background contrast and provides a better 
delineation of the vessel lumen for  in-flow or time-of-flight (TOF) MRA.  
 
How can UHF-CMR benefit low field CMR? 
The increasing flow of knowledge from UHF-CMR technologies and applications are 
advancing the capabilities of clinical CMR at lower field strengths. The move to 7.0 T 
should be handled more thoughtfully than the transition from 1.5 T to 3.0 T, which was 
generally a matter of copy-pasting practices and protocols from a lower field to a 
higher one.  
One area of rethinking concerns developments in RF transmit-receive technology 
that need to be made in connection with ultrahigh field strengths, which has 
catalyzed work on high density RF and antenna arrays in conjunction with 7.0 T.  
Knowledge gained from experience with UHF-CMR can likely be re-applied to 3.0 T. 
Even though RF inhomogeneities and RF power deposition are somewhat offset at 
lower field strengths, their affects are still felt in clinical CMR at 1.5 T and 3.0 T. Moving 
to transmission using local RF coils rather than whole body coils would have a number 
of advantages at 3.0 T. For example, local RF coil transmission was recently used to 
acquire accurate cardiac chamber quantification at 3.0 T 36. Generally, passively 
conducting peripheral implants can be a contraindication for body coil RF 
transmission because of their potential for RF power deposition induced heating. A 
solution would be transmission through local RF coils arranged to exclude peripheral 
implants from excitation. Conductance problems also arise when CMR is used for 
image-guided navigation during the manipulation of catheters, another application 
where local transmission using RF coil arrays is beneficial. They offer additional 
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benefits in that their efficiency in transmission permits reducing the repetition time (TR) 
compared to whole body coil transmission. For example, in a recently reported 2D 
CINE SSFP protocol - the gold standard for cardiac chamber quantification and left 
ventricular (LV) assessment at lower fields – RF power deposition limits imposed a 
minimum repetition time of TR=4.7 ms for body coil transmission and TRmin=3.8 ms for 
local surface coil array transmission 36. This 20% speed gain will likely be highly 
significant in real-time assessments of the heart. A decrease in TR facilitated by local 
RF coil transmission broadens the frequency spectrum of the pass bands in SSFP 
imaging. At 3.0 T this would be helpful for cardiac chamber quantification and 
cardiac function assessment, because the off-resonance effects from SSFP are 
pronounced compared to 1.5 Tesla. Contrary to common experience cardiac 2D 
CINE SSFP images derived with transmit/receive local surface RF coil array at 3.0 T 
exhibit rather uniform signal intensity across the heart as demonstrated in Figure 10. 
The blood/myocardium contrast is clinically acceptable and matches that obtained 
with body coil transmission in conjunction with a local 32 channel receive coil as 
illustrated in Figure 10.  
Another area to profit from UHF-CMR is research targeted at the development of 
novel cardiac gating/triggering techniques. The methods most commonly used in 
clinical CMR currently rely on ECG for gating and triggering, but it is an electrical 
measurement and therefore subject to interference with electromagnetic fields and 
magneto-hydrodynamic effects, which is frequently an obstacle to CMR at 3.0 T and 
becomes worse at higher fields. A suitably simple solution has been found in the form 
of an MR stethoscope. This instrument comprises three main components: (i) an 
acoustic sensor that registers the phonocardiogram, (ii) a signal processing unit that 
detects the first heart tone and transforms it into a trigger signal and (iii) a coupler unit 
to the MRI system 37. Acoustic gating is independent of electromagnetic fields, and 
has been shown to be a robust and safe method of gated/triggered MR in the 
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clinical setting 37, 38. This application is a direct product of early UHF-MR research that 
has already benefitted CMR at 3.0 T and 1.5 T 39.  
 
What obstacles lie on the road to UHF-CMR? 
Pushing the boundaries of magnetic field strengths in CMR presents the same safety 
challenges as the advent of any new clinical technology and must be thoroughly 
tested for its potential physiological impact and physical effects which arise through 
the use of ultrahigh magnetic fields. A key to clinical applications will be to deepen 
our general understanding of the interactions between passive-conducting implants 
and radiofrequency (RF) fields. An increasing number of patients have implants that 
might limit their access to UHF-CMR, until they are shown to be safe at B0 ≥ 7.0 T. Many 
such implants have been deemed MR-safe at lower magnetic field strengths, but this 
will require collecting data about their behaviour when exposed to RF heating in UHF-
CMR. The first assessments of RF-induced heating at B0 ≥ 7.0 T have been carried out 
on passive, conducting implants including intracoronary stents and metallic arterial 
stents. They revealed that the presence of stents did not raise temperatures above 
the standards established by the International Electrotechnical Commission (IEC) 40.  
Fully resolving the safety issue will be complicated a bit by the different thermal 
properties of novel RF antennae configurations, which usually need to be customized 
for 7.0 T MRI, the development of parallel transmission techniques, and the wide 
range of stent geometries that need to be taken into account. An important step 
was made in a recent study of RF-induced heating of coronary stents at 7.0 T 41 based 
on electromagnetic field (EMF) simulations which incorporated many different 
coronary stent configurations. Data from electric fields and local RF power deposition 
were interpreted as a function of the diameter, length, and position of stents relative 
to the RF transmission source and their orientation versus the E-field 41. The results 
provided a model that can be applied to arbitrary geometries and positions of the 
stents and the configurations of diverse RF coils, and we have proposed a transfer 
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function that can predict the EM fields induced in coronary stents 41. This is a quick 
way to assess and predict the levels of RF power disposition that will affect a 
particular stent and configuration. It can be incorporated into state-of-the art SAR 
prediction methods to estimate the SAR that will be induced in coronary stents and 
other conductive implants in response to the arbitrary RF pulses used for transmission 
field shimming or parallel transmission. These criteria should be considered in the 
design of RF coils to ensure low SAR levels in the vicinity of the stent or to achieve 
comparable SAR levels in tissues with and without stents 41.  
These approaches will support and accelerate current safety assessments of coronary 
stents and other implants that are commonly used in clinical practice. They will help 
to show that UHF-CMR is safe – and shape our definitions of what that means. By 
providing a clearer view of the effects of temperature on tissues, the wider range of 
field strengths and coil configurations will add to our understanding of the effects of 
RF energy depositions and provide a more realistic view of factors related to safety, 
especially where limits should be imposed. This should include SAR estimations but 
suggests a move towards a more general standard that can be implemented in the 
upcoming Edition 4 of the IEC 60601-2-33 guideline, which expresses temperature or 
thermal dose in terms of cumulative equivalent minutes at 43°C (CEM43). 
UHF-MR safety assessments must not stop with intracoronary stents. Recent work 
demonstrated the UHF-MR safety of dental wires 42, ocular tantalum markers 43, cranial 
fixation plates 44 and investigated experiences with a broad range of passive implants 
and tattoos 45. Hip implants and other large passive implants being positioned outside 
the excitation field of view of the local transmit/receive RF antennae do not 
constitute a major RF heating issue in UHF-CMR. Further research is required to study 
the UHF-MR safety of sternal wires. 
 
What will the foreseeable future bring? 
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Almost 40.000 human examinations have already been performed at 7.0 T without 
indication that the procedure has acute effects on health 46, 47. The lion's share of UHF-
MR examinations to date has been devoted to the brain and neuroscience, but their 
potential in cardiovascular research is clear and should result in specific clinical 
benefits. Each increase in magnetic field strength pushes the boundaries of 
biomedical imaging and cardiology and provides many other benefits that will help 
translate basic discoveries to the clinic. Joint efforts between basic scientists, 
clinicians and their industry colleagues are already exploring new modes for mapping 
cardiac morphology, function, physiology and metabolism. For every milestone of 
resolution, speed, or contrast that we pass, new routes are opened between basic 
research on cell cultures and animal models and applications in the clinic.  
UHF-CMR has another dimension that may ultimately expand the uses of MR in 
entirely new directions. The RF energy deposition that lies at the heart of MR imaging 
can be used in another way: to deliberately alter temperatures by focusing RF power 
on precise regions of living tissues. This can be accomplished via an MR antenna 
array, creating a new tool with the unique ability to exert very focused, controlled 
changes of temperature. We call this approach thermal magnetic resonance 48, 49 
and believe it can give us control over a crucial biological parameter - temperature - 
that has barely been investigated in cardiology due to technological limitations. 
There has been no systematic thermal phenotyping of diseased tissues, for example, 
where changes in structure, metabolism, and cellular content surely produce 
changes in temperature distribution in meaningful ways. Studies will reveal whether 
UHF-MR guided targeted RF heating for focal RF ablation can be used to terminate 
defective electrical pathways in the heart as an alternative approach to today’s 
invasive intracardiac catheterization in the treatment of tachycardia. 
The extent to which the high cost of 7.0 Tesla magnets can be lowered will depend 
on improved workflows and economic and ergonomic changes to hardware, some 
of which are already underway, such as access to shorter magnets. The first 
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generation of actively shielded 7.0 T magnets offered a length of approximately 255 
cm while the early passively shielded version runs a length of approximately 336 cm. 
These advances have practical effects on the space required by the machines and 
the degree of comfort they provide to patients. Next-generation, actively shielded 
7.0 T MR systems weigh less than 25 tons and are far more compatible with 
installations in clinical imaging suites than the very first generation of 7.0 T class 
systems, which required hundreds of tons of passive shielding.  
On the regulatory side, at least one MR vendor is committed to file an application for 
FDA and CE authorization by 2017, which will be a breakthrough en route to broader 
clinical UHF-MR applications and generate more momentum for clinical pioneers and 
early clinical adaptors in cardiology. This development is supported by the recent 
harmonization of the technical standards and guidelines (Amendment 2 to IEC 60601-
2-33 am2 Ed. 3.0, medical electrical equipment, particular requirements for the basic 
safety and essential performance of magnetic resonance equipment for medical 
diagnosis) of the International Electrotechnical Commission (IEC). This update has 
lifted the limit on the static magnetic field strength for the first level controlled 
operating mode from 4.0 Tesla to 8.0 Tesla, taking into account FDA, ICNIRP and other 
peer-reviewed scientific literature. 
We are just at the starting line of UHF-CMR. Pioneering reports on MR physics, careful 
RF power deposition considerations, and novel RF antenna designs spurred the 
installation of a 10.5 T whole-body MR system at the Center for Magnetic Resonance 
Research, University of Minnesota, Minneapolis, USA 50, with a bore size and system 
architecture that support cardiac MR. The first pioneering reports on body imaging in 
large animals with a weight of 75 kg at 10.5 T have been released, are highly 
encouraging and will open a path towards cardiac MR at 10.5 T 50. 
Physicists, engineers, and pioneers from related disciplines have already taken further 
steps into the future, theoretically, with something they are calling Extreme Field MR 
(EF-MR)47. This envisions human MR at 14.0 Tesla and at 20.0 Tesla 51, 52, and is an 
p a g e  | 17 
 
important conceptual leap; these fields will span even more of the crucial "resolution 
gap" in our understanding of human biology. While the first 20 Tesla class MR 
instruments will likely be devoted to discovery and to proofs-of-principle, findings 
should guide the best use of lower-resolution imaging techniques at lower magnetic 
fields. The only thing that could keep the dream of human MR at 14.0 T or 20.0 T from 
becoming reality would be a lack of conviction to follow the path and see what 
develops. Failing to do so for fear that the clinics will be left behind is to ignore the 
entire recent history of cardiac imaging discovery. When an entire community of 
experts devotes its creative efforts to the task, the gain of knowledge alone will lead 
to answers for questions that we don't yet even know we should ask. 
 
Are we out of the woods yet? 
Viewed at 7.0 Tesla, stimulating anatomical, functional and physiometabolic images 
have already been obtained from the heart. These advances have generated an 
excitement in cardiovascular imaging communities and become a driving force for 
the development of UHF-CMR applications. The remaining challenges should be 
faced openly in collaborations between forward-thinking researchers, clinical 
scientists and clinicians. They should be interdisciplinary, inter-institutional and 
international, as exemplified and spearheaded by the German Ultrahigh Field 
Network (GUFI), the UK7T network and the high field systems and applications study 
group of the ISMRM. One of the basic principles of these networks is that such 
collaborations need to be fair and balanced, because of the true interdisciplinary 
character of the work and the essential role that collective expertise has played 
moving the field forward.   
The heartening pace of discovery is drawing in new talent and driving a transfer of 
the results of UHF-CMR research into the clinical arena, with implications for MR 
physics, biomedical engineering, cardiology, internal medicine, radiology, 
nephrology, and a wide spectrum of related fields of basic research and clinical 
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science. From today's base camp, UHF-CMR may look like mountainous heights; 
inevitably, these peaks will be the low fields of tomorrow. CMR at field strengths of 1.5 
T and 3.0 T has produced marvelous clinical achievements; we can certainly expect 
ultrahigh magnetic fields to produce many more, with benefits in both the low and 
higher field directions. However, this will only happen if we recognize that moving into 
ultrahigh fields is more than just a matter of buying magnets and installing them and 
trying to operate them in "core facilities", armed with the concepts that have guided 
discovery in the lower fields. The ultimate clinical potential of this game-changing 
technology is far greater; all that is required is the imagination to apply it. We will 
always believe that we are at the highest point – until we look up. The goal of such 
predictions is to provide an exciting destination to aim for and push the field as the 
ultrahigh field of today might become the low field of tomorrow. 
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Tables 
 
 
Table 1:  
Synopsis of gains in signal-to-noise ratio (SNR) obtained for cardiovascular MR 
applications at 7.0 T versus lower field strengths. 
 
 
application 
 
imaging technique SNR gain note 
carotid vessel 
wall imaging 27 
2D T1-weighted black 
blood prepared fast 
spin-echo   
 
2.0  
(versus 3.0 T) 
RF coil designs used 
for reception were 
optimized for the 7.0 
T and 3.0 T setup, 3.0 
T and 7.0 T RF coil 
sensitivity similar at 
target 
 
 
cardiac chamber 
quantification 12 
 
2D CINE fast gradient 
echo  
 
2.1  
(versus 1.5 T) 
different RF coil 
designs used for 
signal reception at 
7.0 T and 1. 5T, RF 
coil sensitivity in 
favour of 1.5 T setup 
 
non-contrast 
enhanced,  
time-resolved 
phase velocity 
4D aortic flow 
imaging 21 
 
3D free breathing, 
navigator gated, velocity 
encoded gradient echo 
2.2 
(versus 3.0 T) 
 
3.8 
(versus 1. 5T) 
 
different RF coil 
designs used for 
signal reception at 
7.0 T and 3.0 T/1.5T, 
RF coil sensitivity in 
favour of 3.0 T/1.5 T 
setup 
 
coronary MR 
angiography 10 
 
3D free breathing, 
naviga-tor gated and fat 
suppressed 3D k-space 
segmented fast gradient 
echo 
1.63  
(versus 3.0 T) 
different RF coil 
designs used for 
signal reception at 
7.0 T and 3.0 T, RF 
coil sensitivity in 
favour of 3.0 T setup 
 
31P spectroscopy 
of the septum 19 
UTE-CSI 2.6 - 2.8  
(PCr signal) 
(versus 3.0 T) 
 
same RF coil design 
used at 7.0 T and 3.0 
T 
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Figure Captions 
 
Figure 1:  
Left: Examples of high spatial resolution imaging of cardiac morphology at 7.0 T. These 
short axis views of the heart were derived from fast spin-echo imaging using a spatial 
resolution of top: (0.9 x 0.9 x 4.0) mm3 and bottom: (0.8 x 0.8 x 3.0) mm3. Right: Full field-
of-view and zoomed images of the carotid artery vessel wall acquired with 2D dark 
blood fast spin-echo imaging at 7.0 T using an in-plane spatial resolution of (0.55 x 
0.55) mm2. For imaging a 4 channel transceiver RF building block (Figure 2d) 
comprising four loop elements was used for each carotid. The phase setting for each 
loop element was tailored for enhancing transmission field uniformity around the 
carotids. 
 
 
Figure 2:  
Four chamber views of the heart of a healthy subject acquired at 7.0 T using a) a four 
channel loop, b) an eight channel loop, c) a sixteen channel loop, d) a thirty-two 
channel loop and e) a sixteen channel bow tie antenna transceiver RF array. For 2D 
the CINE FLASH acquisitions of the four chamber views a spatial resolution of (1.4 x 1.4. 
x 4.0) mm3 was used for all RF array configurations. 
 
Figure 3:  
Left) End-diastolic short axis views covering the heart from the apex to the base 
showing rather uniform signal intensity and no major signal voids. Images were 
derived from 2D CINE FLASH imaging using a spatial resolution of (1.1 x 1.1 x 2.5) mm3 
and a 16 channel transceiver bow tie antenna RF array at 7.0 T. (The supplemental 
online video shows a video encompassing all cardiac phases.) Right) Four chamber 
views (left) and short axis views (right) of the heart derived from 2D CINE FLASH 
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acquisitions at 7.0 T using a standardized clinical protocol with a spatial resolution of 
(1.8 x 1.8x6.0) mm3 (top) and an enhanced spatial resolution of  (1.1 x 1.1x2.5 ) mm3 
(bottom). The latter constitutes a six-fold improvement in spatial resolution over the 
standardized CMR protocol. 
 
Figure 4:  
A three chamber view (left) and a short axis view (right) of the heart of a hypertrophic 
cardiomyopathy patient showing myocardial crypts (white arrows) in the 
anteroseptal region of the heart5. Images were acquired at 7.0 T using 2D CINE 
gradient-echo imaging with a spatial resolution of (1.4 x 1.4 x 4.0) mm3. 
 
Figure 5:  
Examples derived from free breathing real time imaging of the heart at 7.0 Tesla: a 
four-chamber view (left), a mid-ventricular short axis view (center) and a two-
chamber view of the heart (right). Images were acquired at a rate of 30 frames per 
second and a spatial resolution of (1.2 x 1.2 x 6.0) mm3 23.  
 
Figure 6: 
UHF-CMR permits 2D CINE T2* mapping across the entire cardiac cycle. top) A 
magnitude image and a T2*-map of an end-diastolic short axis view of the heart 
obtained for a healthy subject at 7.0 T. center) A magnitude image and a T2*-map of 
an end-systolic short axis view of the heart obtained for a patient with hypertrophic 
cardiomyopathy at 7.0 T. bottom) Phase-resolved, high resolution T2* mapping at 7.0 T 
revealed that septal T2* correlates with myocardial wall thickness (left) and LV inner 
radius (right) in healthy volunteers at 7.0 T22. Error bars in scatter plots indicate SEM. 
 
Figure 7: 
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A CINE series of sodium images of the heart covering the entire cardiac cycle with a 
temporal resolution of 0.1 s. For data acquisition and reconstruction of the transversal 
view of the heart, a nominal isotropic spatial resolution of 6 mm3 was used 34.  
 
 
 
Figure 8: 
Examples for phosphorous (31P) MR spectroscopy in healthy subjects19 (top) and 
patients with dilated cardiomyopathy6 (bottom) at 7.0 T (red lines) and at 3.0 T (blue 
lines). The 31P MR spectra were derived from a myocardial region located in the 
middle of the interventricular septum of the heart. 31P MRS at 7.0 T provided a 
substantial SNR advantage (SNRgain,PCr=2.6-2.8) over 31P MR spectroscopy at 3.0 T. 
Image courtesy of Christopher Rodgers, Radcliffe Department of Medicine, University 
of Oxford, Oxford, UK. 
 
Figure 9: 
Examples of large field of view cardiovascular imaging derived from non-contrast 
enhanced free breathing real time imaging (left), segmented 2D CINE FLASH imaging 
(center) and 4D MR flow imaging (right) of the aorta at 7.0 T. The accelerated 
imaging capabilities at 7.0 T and the anatomical coverage of the 16 channel bow tie 
antenna array used for transmission and reception (Figure 2) supported free 
breathing real time imaging of the aorta at a rate of 30 frames per second using 
highly undersampled radial 2D FLASH with nonlinear inverse reconstruction at a 
spatial resolution of (1.2 x 1.2 x 6.0) mm3. For comparison conventional, segmented 2D 
CINE FLASH imaging of the same slice was conducted with an in-plane spatial 
resolution of (1.1 x 1.1 x 2.5) mm3. The real time and the 2D CINE FLASH images of the 
aorta demonstrate the 35 cm anatomic coverage of the 16 channel bow tie 
antenna array along the head-feet direction including. Right: Pathline visualization of 
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blood velocity within the human aorta at t=306 ms relative to R-wave of the ECG 
signal. Data were obtained from 4D flow measurements at 7.0 T using 1.2 mm 
isotropic spatial and 40.8 ms temporal resolution. 4D flow image (right) courtesy of 
Sebastian Schmitter, Germany Metrology Institute, Berlin, Germany and Center for 
Magnetic Resonance Research, University of Minnesota Medical School, Minneapolis, 
USA. 
 
 
Figure 10:  
Four chamber and two chamber views of the heart of a healthy human subject 
obtained with 2D CINE SSFP imaging at 3.0 T. For CMR a local 4 channel surface 
transceiver RF coil array (left) was used. As a comparison, traditional body RF coil 
transmission was used in conjunction with a local 4 channel receive RF coil array 
(middle) or with a local 32 channel receive RF coil array (right) 36. The uniformity of 
signal intensity across the heart and the blood/myocardium contrast obtained with 
local surface coil transmission match that obtained with body coil transmission. 
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